XML 48 R38.htm IDEA: XBRL DOCUMENT v3.25.3
INVESTMENTS – RELATED PARTIES (Tables)
 9 Months Ended
Sep. 30, 2025
SEC Schedule, 12-15, Insurance Companies, Summary of Investments, Other than Investments in Related Parties [Abstract]  
Schedule of investment
                
   Interest     September 30,   December 31, 
   Rate  Due Date  2025   2024 
Promissory note and accrued interest receivable, Ault & Company  8%  December 31, 2024  $-   $2,468,000 
Promissory notes and accrued interest receivable, GIGA  6% - 15%  In bankruptcy   27,761,000    18,499,000 
Other         335,000    335,000 
Allowance for credit losses         (500,000)   (500,000)
Total investment in promissory notes and other, related parties        $27,596,000   $20,802,000 
Schedule of Interest income, related party
                
   For the Three Months Ended   For the Nine Months Ended 
   September 30,   September 30, 
   2025   2024   2025   2024 
Interest income, related party  $566,000   $337,000   $1,714,000   $815,000 
Schedule of investment in common stock
            
   Investments in Common Stock, Related Parties at September 30, 2025 
   Cost   Gross Unrealized Losses   Fair value 
Common shares  $24,394,000   $(24,310,000)  $84,000 
Alzamend series B convertible preferred stock, warrants   839,000    -    839,000 
   $25,233,000   $(24,310,000)  $923,000 

 

   Investments in Common Stock, Related Parties at December 31, 2024 
   Cost   Gross Unrealized Losses   Fair value 
Common shares  $24,697,000   $(24,607,000)  $90,000 
Alzamend series B convertible preferred stock, warrants   2,100,000    -    2,100,000 
   $26,797,000   $(24,607,000)  $2,190,000 
Schedule of investment in warrants and common stock
          
   For the Three Months Ended September 30, 
   2025   2024 
Balance at July 1  $24,000   $304,000 
Conversion of Alzamend series B convertible preferred stock to common stock   1,261,000    - 
Sale of Alzamend common stock   (1,268,000)   - 
Realized gain in common stock of Alzamend   70,000    - 
Unrealized loss in common stock of Alzamend   (3,000)   (173,000)
Balance at September 30  $84,000   $131,000 

 

The following tables summarize the changes in the Company’s investments in Alzamend common stock during the nine months ended September 30, 2025 and 2024:

 

   For the Nine Months Ended September 30, 
   2025   2024 
Balance at January 1  $90,000   $679,000 
Investment in common stock of Alzamend   8,000    9,000 
Conversion of Alzamend series B convertible preferred stock to common stock   1,261,000    - 
Sale of Alzamend common stock   (1,274,000)   - 
Realized loss in common stock of Alzamend   (298,000)   - 
Unrealized gain (loss) in common stock of Alzamend   297,000    (557,000)
Balance at September 30  $84,000   $131,000 
Schedule of investment in warrants and preferred stock
          
   September 30,   December 31, 
   2025   2024 
Investment in Alzamend preferred stock  $839,000   $2,100,000 
Total investment in other investments securities, related party  $839,000   $2,100,000